Kaitlin B Baron1, Jennifer R Brown1, Brian L Heiss1, Joanne Marshall1, Nancy Tait1, Katherine H R Tkaczuk1, Stephen S Gottlieb2. 1. University of Maryland School of Medicine, Divisions of Cardiology and Hematology/Oncology, Department of Medicine, Baltimore, MD. 2. University of Maryland School of Medicine, Divisions of Cardiology and Hematology/Oncology, Department of Medicine, Baltimore, MD. Electronic address: sgottlie@medicine.umaryland.edu.
Abstract
BACKGROUND: Although it is known that trastuzumab causes cardiotoxicity, its extent and reversibility are still in question. Earlier studies have not evaluated consecutive patients with reproducible nuclear ventriculography. OBJECTIVE: We sought to evaluate the baseline characteristics which predispose patients to increased risk of trastuzumab cardiotoxicity and to determine the natural history of the cardiotoxicity. METHODS AND RESULTS: Left ventricular ejection fraction (LVEF) was measured in 76 women aged 36-73 years who had been treated with trastuzumab at the University of Maryland Greenebaum Cancer Center. LVEF was determined at baseline and then 3, 6, 9, and 12 months after treatment initiation. Cardiotoxicity was defined as ≥ 16% decrease in LVEF or ≥ 10% decrease in LVEF to <50%. There were no differences in comorbidities, earlier treatment, or demographics between patients with and without trastuzumab-induced cardiomyopathy except that African Americans were more likely to develop decreased LVEF (P < .05). Twenty-one patients (28%) met criteria for cardiotoxicity. Four of those patients were continued on trastuzumab and 17 patients had therapy withheld at some point. Only 1 patient developed symptomatic heart failure requiring inpatient hospitalization. LVEF improved in most patients regardless of whether or not trastuzumab was continued. CONCLUSIONS: Decreased LVEF while undergoing trastuzumab therapy occurs frequently and is usually reversible. African Americans had a higher risk of developing decreased LVEF. These findings raise clinically important questions as to whether it is necessary to discontinue trastuzumab for asymptomatic decrease in LVEF and whether African Americans are more predisposed to a decrease in LVEF while receiving trastuzumab. Further studies carefully assessing LVEF should address these hypotheses.
BACKGROUND: Although it is known that trastuzumab causes cardiotoxicity, its extent and reversibility are still in question. Earlier studies have not evaluated consecutive patients with reproducible nuclear ventriculography. OBJECTIVE: We sought to evaluate the baseline characteristics which predispose patients to increased risk of trastuzumab cardiotoxicity and to determine the natural history of the cardiotoxicity. METHODS AND RESULTS: Left ventricular ejection fraction (LVEF) was measured in 76 women aged 36-73 years who had been treated with trastuzumab at the University of Maryland Greenebaum Cancer Center. LVEF was determined at baseline and then 3, 6, 9, and 12 months after treatment initiation. Cardiotoxicity was defined as ≥ 16% decrease in LVEF or ≥ 10% decrease in LVEF to <50%. There were no differences in comorbidities, earlier treatment, or demographics between patients with and without trastuzumab-induced cardiomyopathy except that African Americans were more likely to develop decreased LVEF (P < .05). Twenty-one patients (28%) met criteria for cardiotoxicity. Four of those patients were continued on trastuzumab and 17 patients had therapy withheld at some point. Only 1 patient developed symptomatic heart failure requiring inpatient hospitalization. LVEF improved in most patients regardless of whether or not trastuzumab was continued. CONCLUSIONS: Decreased LVEF while undergoing trastuzumab therapy occurs frequently and is usually reversible. African Americans had a higher risk of developing decreased LVEF. These findings raise clinically important questions as to whether it is necessary to discontinue trastuzumab for asymptomatic decrease in LVEF and whether African Americans are more predisposed to a decrease in LVEF while receiving trastuzumab. Further studies carefully assessing LVEF should address these hypotheses.
Authors: Naomi Dempsey; Amanda Rosenthal; Nitika Dabas; Yana Kropotova; Marc Lippman; Nanette H Bishopric Journal: Breast Cancer Res Treat Date: 2021-06-11 Impact factor: 4.872
Authors: Anya Litvak; Bhavina Batukbhai; Stuart D Russell; Hua-Ling Tsai; Gary L Rosner; Stacie C Jeter; Deborah Armstrong; Leisha A Emens; John Fetting; Antonio C Wolff; Raquel Silhy; Vered Stearns; Roisin M Connolly Journal: Cancer Date: 2018-01-30 Impact factor: 6.860
Authors: Sherry-Ann Brown; Svetlana Zaharova; Peter Mason; Jonathan Thompson; Bicky Thapa; David Ishizawar; Erin Wilkes; Gulrayz Ahmed; Jason Rubenstein; Joyce Sanchez; David Joyce; Balaraman Kalyanaraman; Michael Widlansky Journal: Front Cardiovasc Med Date: 2020-12-04
Authors: Mohammed Al-Sadawi; Yasin Hussain; Robert S Copeland-Halperin; Jonathan N Tobin; Chaya S Moskowitz; Chau T Dang; Jennifer E Liu; Richard M Steingart; Michelle N Johnson; Anthony F Yu Journal: Am J Cardiol Date: 2021-02-20 Impact factor: 2.778
Authors: Fangyuan Zhao; Brenda Copley; Qun Niu; Fang Liu; Julie A Johnson; Thomas Sutton; Galina Khramtsova; Elisabeth Sveen; Toshio F Yoshimatsu; Yonglan Zheng; Abiola Ibraheem; Nora Jaskowiak; Rita Nanda; Gini F Fleming; Olufunmilayo I Olopade; Dezheng Huo Journal: Breast Cancer Res Treat Date: 2020-10-27 Impact factor: 4.872